GlassScriptPhysician profile
John Alan Vande Waa
NPI 1447290630
$5,273.28
in general payments reported to CMS, 2019-2025
22 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $128 · 2021: $399 · 2022: $853 · 2023: $745 · 2024: $1,023 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,315.16 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $1,207.16 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Gilead Sciences, INC. | $1,019.38 | 2019-2025 | Biktarvy |
| Melinta Therapeutics, LLC | $468.85 | 2021-2024 | Kimyrsa, Rezzayo, Vabomere |
| Janssen Biotech, INC. | $277.66 | 2021-2023 | Symtuza |
| Janssen Products, LP | $164.98 | 2019-2022 | |
| Shionogi INC | $135.04 | 2022-2024 | Fetroja |
| Astellas Pharma US INC | $134.88 | 2019-2024 | Cresemba |
| Theratechnologies INC. | $106.80 | 2019-2023 | Egrifta, Trogarzo |
| Abbvie INC. | $81.65 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $67.19 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $65.03 | 2024-2025 | Acthar |
| Regeneron Pharmaceuticals, INC. | $34.15 | 2022 | |
| Vyera Pharmaceuticals, LLC | $30.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.55 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.26 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.72 | 2024 | Uptravi, Opsumit |
| Ferring Pharmaceuticals INC. | $22.70 | 2024 | Rebyota |
| Invivyd INC | $21.14 | 2025 | Pemgarda |
| Shire North American Group INC | $16.76 | 2019 | |
| United Therapeutics Corporation | $16.74 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.64 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vande Waa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.